key: cord-0784212-jxbdgn5a authors: Koh, Huilin; Moh, Angela Mei Chung; Yeoh, Ester; Lin, Yi; Low, Serena Kiat Mun; Ooi, Say Tat; Tan, Seng Kiong; Lin, Jaime Hui Xian; Hoong, Caroline Wei Shan title: Diabetes predicts severity of COVID‐19 infection in a retrospective cohort: A mediatory role of the inflammatory biomarker C‐reactive protein date: 2021-02-09 journal: J Med Virol DOI: 10.1002/jmv.26837 sha: 2879d27115ca08f35fd786e78c7df4bc1955a6a4 doc_id: 784212 cord_uid: jxbdgn5a Diabetes is a risk factor for developing severe COVID‐19, but the pathogenesis remains unclear. We investigated if the association of diabetes and COVID‐19 severity may be mediated by inflammation. We also hypothesized that this increased risk may extend to prediabetes. Hospitalized patients in Singapore with COVID‐19 were subdivided into three groups in a retrospective cohort: normoglycemia (HbA1c: ≤5.6%), prediabetes (HbA1c: 5.7%–6.4%) and diabetes (HbA1c: ≥6.5%). The primary outcome of severe COVID‐19 was defined by respiratory rate ≥30, SpO2 ≤93% or intensive care unit admission. The association between clinical factors on severe COVID‐19 outcome was analyzed by cox regression. Adjusted mediation analysis of C‐reactive protein (CRP) on the relationship between diabetes and severe COVID‐19 was performed. Of 1042 hospitalized patients, mean age 39 ± 11 years, 13% had diabetes, 9% prediabetes and 78% normoglycemia. Severe COVID‐19 occurred in 4.9% of subjects. Compared to normoglycemia, diabetes was significantly associated with severe COVID‐19 on both univariate (hazard ratio [HR]: 9.94; 95% confidence interval [CI]: 5.54–17.84; p < .001) and multivariate analysis (HR: 3.99; 95% CI: 1.92–8.31; p < .001), while prediabetes was not a risk factor (HR: 0.94; 95% CI: 0.22–4.03; p = .929). CRP, a biomarker of inflammation, mediated 32.7% of the total association between diabetes and severe COVID‐19 outcome. In conclusion, CRP is a partial mediator of the association between diabetes and severe COVID‐19 infection, confirming that inflammation is important in the pathogenesis of severe COVID‐19 in diabetes. unit (ICU) admission and mortality in COVID-19 patients with diabetes, 4,7 the pathogenesis remains unclear. Diabetes has been described as a chronic inflammatory state evident by raised inflammatory markers such as C-reactive protein (CRP). 8 Hyperglycemia upregulates the expression of proinflammatory cytokines, setting up the stage for a hyper-inflammatory response in acute infection, 9, 10 which has been proposed to result in multiorgan failure and death in COVID-19. 10, 11 Interestingly, long-term glycemic control was not consistently associated with COVID-19 severity and mortality. 12, 13 Emerging evidence have shown the importance of inpatient hyperglycemia as a significant predictor of adverse outcomes, in patients with and without diabetes. 14, 15 Although studies have demonstrated the association between hyperglycemia and an impaired innate and adaptive immune system, increasing the risk of sepsis, 16,17 it is uncertain at what threshold of hyperglycemia this occurs. The impact of prediabetes on COVID-19 outcomes is lacking in the literature. Fasting glucose exceeding 5.6 mmol/L was associated with increased nonvascular, noncancer deaths and all-cause mortality. 18 Similarly, a large meta-analysis demonstrated prediabetes to be a risk factor for all-cause mortality. 19 However, few studies have investigated the significance of prediabetes in sepsis and acute illness. Impaired fasting glucose was found to predict an adverse prognosis among hospitalized patients with COVID-19. 20 There was, however, no available glycated hemoglobin (HbA1c) data to establish longer-term glycemic control to distinguish inpatient stress-induced hyperglycemia from prediabetes. Given that the population prevalence of prediabetes is estimated at 13.5%-58% depending on the definition used, 21 an excess risk identified could have substantial impact on morbidity and mortality in this COVID-19 pandemic. The association between diabetes and severity of COVID- 19 infection has previously been demonstrated, but the mechanisms for this are unclear. In this study, we sought to confirm if the presence of diabetes was associated with poorer COVID-19 outcomes, and if so, whether they were mediated by a proinflammatory state. Using CRP as a biomarker of inflammation, we hypothesize that diabetes was associated with an increased risk of severe COVID-19 via a heightened inflammatory burden. As identifying modifiable risk factors could be helpful in devising new therapeutic strategies in our longerterm fight against COVID-19, a secondary aim was to identify factors associated with adverse outcomes in patients hospitalized with COVID-19 infection, particularly inpatient hyperglycemia, as well as longer-term glycemic control as measured by HbA1c. Last, we also explored prediabetes as a possible adverse prognostic factor which would emphasize the need for preventive strategies. Singapore has one of the world's lowest mortality rate for COVID-19, 2 postulated to be due to several factors including early detection, extensive contact tracing, younger demographics, preemptive hospitalization even if well, and mandatory mask-wearing which have been shown to reduce not just infection rates but severity of illness in those infected. 22 Hence, the setting of this cohort in Singapore implies the vast majority are clinically well due to the Ministry of Health's adopted strategy to admit all patients diagnosed with COVID-19 to hospitals or community facilities for monitoring and isolation. 1 Baseline CRP level was obtained within the first 48 h of admission. All patients admitted for COVID-19 had a predefined set of laboratory investigations to be performed and HbA1c or glucose was not part of this routine set. Exclusion criteria included pregnancy and those with missing data on the primary outcome of oxygen saturation, respiratory rate or admission to ICU. Diabetes mellitus (DM) was defined as HbA1c ≥6.5% 23 or selfreported history of diabetes or use of glucose-lowering medications. Prediabetes (pre-DM) and normoglycemia were defined as HbA1c 5.7-6.4 or HbA1c ≤5.6%, respectively, without a selfreported history of diabetes or use of glucose-lowering medications. The primary outcome was defined as the development of severe COVID-19, defined by SpO2 ≤93% on room air, respiratory rate ≥30 24 or need for ICU care. In addition, we compared length of stay, dyspnea (defined by respiratory rate ≥30 or SpO2 ≤93%), need for ICU and mortality. Statistics were performed using STATA version 14 (Stata). Continuous variables were presented as mean ± SD or median (interquartile range [IQ]), and categorical data were shown as n (%). The Student t test and Mann-Whitney U test were used to compare differences of continuous variables between two independent groups; and χ 2 test was used to compare categorical variables. Nonnormally distributed continuous variables were natural logtransformed before regression analysis. Cox proportional hazards regression was used to analyze the association between baseline factors and events of severe COVID-19, dyspnea or ICU admission, while linear regression was used to analyze the outcome of inpatient length of stay. Considering that the number of adverse events was small, only four variables (age, sex, body mass index [BMI] , and having ≥2 comorbidities), selected a priori, 25 were included as covariates in the regression models to avoid overfitting issues. Adjusted mediation analysis was performed to examine the mediatory effect of CRP, LDH, and hypoglycemia on the relationship between DM and the inpatient outcomes using the STATA "binary_mediation" (for binary outcome) and "sgmediation" A total of 1042 subjects were hospitalized with COVID-19 infection ( Table 1 ). The predominantly male cohort (95%) of relatively young age (mean: 39 ± 11 years) was due to Singapore's outbreak of COVID-19 among foreign worker dormitories and a low community transmission rate. 27 Subjects were classified as DM, pre-DM and normoglycemia in 13%, 9% and 78%, respectively. The mean BMI was 24.2 kg/m 2 , as defined by the World Health Organization criteria of BMI in Asians, 28 with 62% being overweight or obese. The difference in BMI was significant between DM status groups (p-trend <0.001) with highest mean BMI 25.5 kg/m 2 in the DM group. Overall, 7% of subjects had ≥2 comorbidities of hypertension, hyperlipidemia, cardiovascular disease (CVD), chronic kidney disease (CKD), chronic respiratory disease excluding the presence of diabetes. A significantly higher proportion of subjects with DM (33%) had ≥2 comorbidities as compared to the pre-DM (12%) and normoglycemia (1%) groups (p-trend <0.001; Table S1 ). Admission glucose levels were significantly different between DM status groups: 12.1 mmol/L in DM, 7.4 mmol/L in pre-DM, and 6.2 mmol/L in normoglycemia patients (p-trend <0.001) ( Table 1 ). The mean HbA1c was 8.5%, 5.9% and 5.4% in the DM, pre-DM and normoglycemia groups, respectively (p-trend <0.001). The admission glucose and average glucose during hospitalization were also significantly higher in the DM group compared to other groups. Of the subjects with DM, 89% were on glucose-lowering agents and 15% were on insulin. Median CRP at admission was low at 3.7 (1. Table S1 . The primary outcome of severe COVID-19 infection occurred in 51 patients (4.9%) of the overall cohort (Table 1) . A total of 27 (2.6%) patients were admitted to ICU, 46 (4.4%) developed dyspnea, and 5 (0.5%) demised. The median length of stay was 8 (IQ: 5-12) days. A significantly greater proportion of subjects with DM developed the primary outcome of severe COVID-19 (22%) as compared to pre-DM (2%) and normoglycemia (2%) subjects, respectively (Table 1 ). This was verified on Cox regression, where diabetes was significantly associated with the occurrence of severe COVID-19 on both univariate ( This trend towards more severe illness in subjects with DM was also consistent in the secondary outcomes of developing dyspnea and requiring ICU admission, as compared to pre-DM and normoglycemia groups ( Table 1) . After adjusting for significant confounders, the presence of DM was associated with an increased HR of 4.05 (95% CI: 1.94-8.43) p < .001 for developing dyspnea, and HR of 10.93 (95% CI: 3.54-33.77) p < .001 for requiring ICU admission compared to normoglycemic patients ( Table 3) . Length of stay was significantly longer in DM subjects compared to other groups (Table 1) . This was consistently observed in the univariate and multivariate analyses (Table 3) . Mortality was higher in DM subjects, however, it did not reach statistical significance due to very low mortality in the cohort (0.5%). In contrast, prediabetes was not associated with the occurrence of severe COVID-19 disease compared to the normoglycemia group on KOH ET AL. (Table 2 ). In addition, patients with pre-DM and normoglycemia had similar secondary outcomes with respect to development of dyspnea (p = .503), need for ICU care (p = .607) and length of stay (p = .055). Using HbA1c as a measure of long-term glycemic control, there was no difference in primary outcome of developing severe COVID-19 infection when 109 DM subjects with available HbA1c measurements were stratified according to HbA1c thresholds of less than or greater than 9%, 8%, and 7% (Table S2 ). In the overall cohort, admission hyperglycemia was associated with a 6% increased risk of COVID-19 severity, however, significance was lost on adjusted analysis ( As shown in Table 3 Our findings that DM is associated with poorer COVID-19 prognosis, including longer inpatient stay and severe pneumonia requiring admission to ICU, are consistent with findings from other centers worldwide. 5, 6 Other comorbidities such as hypertension, CVD, chronic respiratory disease, and CKD identified to be adverse prognostic factors in our study have also been confirmed in other cohorts. 5, 29 In patients with DM, an exaggerated immune response to 16 However, it is also important to note that the effect of inflammation as measured by CRP on COVID-19 severity is not solely modulated by DM status. Other factors apart from DM that modulate vascular inflammation, such as the presence of CVD, malignancy or smoking status, may also influence COVID-19 outcomes, however, it was not possible to explore these associations in the scope of this study. As CRP only mediated a portion of the association between diabetes and severe COVID-19 outcomes, other factors may play an important role. Inpatient hypoglycemia has also been known to be correlated with mortality in hospitalized patients, possibly related to cardiovascular and neurological complications. 32 Although there was a greater number of hypoglycemic events in patients with DM compared to non-DM subjects in our cohort, hypoglycemia was not a significant mediator on the severity of COVID-19 disease in DM patients. Furthermore, although LDH level was strongly associated with severe COVID-19 disease, which was similar to other reports, 33 LDH did not mediate the association between DM and severe COVID-19 outcome. LDH is an intracellular enzyme which catalyzes the interconversion of pyruvate and lactate found in cells throughout all organ systems. While CRP is an acute phase reactant, LDH is a biomarker that indicates the degree of tissue damage. 33 This may suggest a differential role of the inflammatory biomarkers CRP and LDH in predicting poorer outcomes in COVID-19 patients with and without DM respectively. As CRP was only a partial mediator of DM on COVID-19 severity, the authors propose that other potential mediators of adverse COVID-19 outcomes in DM, such as D-dimer or other prothrombotic markers, 34 could be further investigated, as diabetes has been described to be a hypercoagulable state in addition to a chronic inflammatory state. 35 Hence, inflammation alone as determined by the biomarker CRP could not entirely mediate the association of adverse outcomes observed in patients with diabetes. Our study is among the first to investigate the association between pre-diabetes and COVID-19 outcomes. Normoglycemia, prediabetes and DM exist in the continuum. Therefore, we expected a higher baseline CRP level (representative of the proinflammatory state) and a higher incidence of severe COVID-19 in the prediabetes group as compared to the normoglycemia group. However, our study suggested that prediabetes was not associated with a higher baseline CRP level or increased incidence of severe COVID-19 disease. T A B L E 4 Mediation effects of C-reactive protein on the relationship between DM (vs. non-DM) and inpatient events Note: All models were adjusted for baseline covariates including age, sex, BMI, ≥2 comorbidities (including HTN, HLD, CVD, CRD, and CKD). Abbreviations: BMI, body mass index; DM, diabetes mellitus; CKD, chronic kidney disease; CRD, chronic respiratory disease; CRP, C-reactive protein (natural log-transformed); CVD, cardiovascular disease; HLD, hyperlipidaemia; HTN, hypertension; ICU, intensive care unit; LOS, length of stay. This supports the findings from a recent study. 36 Even though primary outcome event numbers were small in this group to draw a definitive conclusion, there was no trend towards poorer outcomes, even with baseline CRP level. A graded increase in some biomarkers of inflammation such as white cell count and fibrinogen was reported from normoglycemia to prediabetes to diabetes, while other markers such as neopterin, albumin, and hematocrit showed no such changes in prediabetes. 37 If the subclinical effects of immune dysregulation were small in prediabetes, the low incidence of severe outcomes in our cohort may have precluded the ability of our study to elucidate such effects. To date, in individuals with dysglycemia, the duration and degree of exposure to hyperglycemia required to incite chronic inflammation and immune dysfunction is unknown. The impact of prediabetes on the morbidity and mortality of COVID-19 infection needs to be addressed in future studies. In our study, both admission and inpatient hyperglycemia among DM patients were not associated with an adverse outcome. However, in the overall cohort, there was a trend to a poorer outcome with admission hyperglycemia. As less than two-thirds of the cohort of subjects without diabetes had an admission glucose measured, it was not possible to draw conclusions from this group. Interestingly, studies consistently found a stronger association between hyperglycemia and adverse outcomes in COVID-19 patients without diabetes than in patients with preexisting diabetes, 13, 15, 16, 38 likely reflecting the severity of critical illness resulting in stress-induced hyperglycemia and severe insulin resistance in nondiabetic patients. 39 Adaptation to chronic hyperglycemia in preexisting diabetes may account for these differences, as evidenced by a lack of benefit for intensive glucose control in critically-ill patients with diabetes compared to nondiabetes in a landmark trial, which was not explained by more hypoglycemic events. 40 There have been variable observations on the effect of poor The low mortality rate (0.5%) and low occurrence of severe Strengths of the study should be acknowledged. All patients were diagnosed with COVID-19 via validated RT-PCR methods in the current admission rather than using a clinical diagnosis. The use of HbA1c data in addition to a self-reported history of diabetes increased the detection of newly diagnosed diabetes. As opposed to the use of fasting plasma glucose, HbA1c data allowed a clearer distinction between stress-induced hyperglycemia with and without diabetes. Given the impossibility in proving causality in the COVID-19 pandemic with observational studies, the use of mediation analysis in this study strengthens the causal association between diabetes, inflammation and development of severe outcomes. This study consistently demonstrates diabetes to be associated with all measures of adverse COVID-19 outcomes, including severity, need for ICU admission, development of dyspnea and length of stay in both unadjusted and adjusted models. CRP was a partial mediator of the association between diabetes and these adverse outcomes, confirming that inflammation is an important process in the pathogenesis of severe COVID-19 in diabetes. More studies are required to elucidate other mechanisms which contribute to the severe COVID-19 outcomes observed in diabetes. In this population of patients with diabetes, inpatient hyperglycemia and longer term glycemic control as measured by HbA1c were not associated with severe COVID-19 infection. Prediabetes has not been identified so far to be an adverse prognostic marker in COVID-19, although larger studies are required to clarify this. Nonetheless, those with prediabetes remains an important group to target with population-based prevention strategies before they progress to diabetes which is unequivocally linked to poorer outcomes. The authors declare that there are no conflict of interests. The peer review history for this article is available at https://publons. com/publon/10.1002/jmv.26837. The data that support the findings of this study are available from the corresponding author upon reasonable request. Ester Yeoh https://orcid.org/0000-0002-2686-9412 Seng Kiong Tan https://orcid.org/0000-0002-4754-2152 Caroline Wei Shan Hoong https://orcid.org/0000-0002-5206-5477 Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures Update (Live): 83,980,234 Cases and 1,828,875 Deaths from COVID-19 Virus Pandemic -Worldometer Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis Sanchis-Gomar F. Diabetes mellitus association with coronavirus disease COVID-19) severity and mortality: a pooled analysis The impact of obesity on COVID-19 complications: a retrospective cohort study Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome C-reactive protein and glycemic control in adults with diabetes Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress COVID-19: consider cytokine storm syndromes and immunosuppression COVID-19 pandemic, coronaviruses, and diabetes mellitus Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study Preadmission Diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019 Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 study Immune dysfunction in patients with diabetes mellitus (DM) Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections Diabetes mellitus, fasting glucose, and risk of cause-specific death Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated metaanalysis Impaired fasting glucose and diabetes are related to higher risks of complications and mortality among patients with coronavirus disease 2019 Prevalence of prediabetes across ethnicities: a review of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) for classification of dysglycaemia Facial masking for Covid-19-potential for "Variolation" as we await a vaccine American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020 Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Lowering glucose to prevent adverse cardiovascular outcomes in a critical care setting Dexamethasone in hospitalized patients with Covid-19-preliminary report Mortality among hospitalized patients with hypoglycemia: insulin related and noninsulin related Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis Clinical characteristics of diabetic patients with COVID-19 Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19 Stress hyperglycemia in critically ill patients: insight into possible molecular pathways Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm Factors associated with COVID-19-related death using OpenSAFELY Covid-19: England comes into line with rest of UK on recording deaths Analysis of death registrations not involving coronavirus (COVID-19) The risk of diabetes on clinical outcomes in patients with coronavirus disease 2019: a retrospective cohort study Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: a retrospective single centre study Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a wholepopulation study Type 2 diabetes and COVID-19-related mortality in the critical care setting: a national cohort study in England Diabetes predicts severity of COVID-19 infection in a retrospective cohort: A mediatory role of the inflammatory biomarker C-reactive protein